WuXi Biologics of Shanghai formed a collaboration with San Francisco's Vir Biotech to develop mAbs that treat COVID-19. By examining people who survived the SARS infection, Vir used its technology to identify several mAbs that bind to SARS-CoV-2. It will test these molecules to see if they are effective treatments for COVID-19. WuXi, which will be in charge of developing and manufacturing any promising candidates, will have China rights to any approved treatments developed by the collaboration, while Vir will own rest-of-the-world commercialization rights. More details....
Stock Symbols: (HK: 2269) (NSDQ: VIR)
Share this with colleagues:
Original Article: WuXi Biologics and Vir Biotech Team up to Develop COVID-19 Antibodies